Diabetes Clinical Trial
Official title:
Randomized, Double-blind, Placebo-controlled, Dose Escalated Tolerance and Pharmacokinetic / Pharmacodynamic Studies of SY-008 Capsules Administered by Chinese Healthy Subjects
Verified date | October 2019 |
Source | Suzhou Yabao Pharmaceutical R&D Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase Ⅰ,single-center, randomized, double-blinded, placebo-controlled, single ascending dose trial of SY-008 in healthy subjects.
Status | Completed |
Enrollment | 54 |
Est. completion date | December 30, 2018 |
Est. primary completion date | December 30, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Gender: Male and female, gender balance. 2. Age: 18-65 years old (including the boundary values). 3. Weight =50kg and 19kg / m2 = BMI = 28kg / m2 [BMI = body weight (kg) / height 2 (m2). 4. fasting plasm glucose (FPG): 3.9-6.1mmol / L (excluding the boundary values). 5. glycosylated hemoglobin (HbA1c) <6.5%. 6. healthy subjects determined by medical history, physical examination, electrocardiogram and laboratory tests. Test results within the normal range for the population or investigator site, or with abnormalities deemed clinically insignificant by the investigator. 7. have venous access sufficient to allow blood sampling as per the protocol. 8. have given written informed consent approved by sponsors and the ethical review board governing the site. 9. are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures. Exclusion Criteria: 1. are investigator site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted. 2. within 3 months prior to screening, complete or withdraw a clinical study, or are currently conducting a clinical study. Or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. 3. have previously completed or withdrawn from this study. 4. 2h postprandial plasm glucose (2hPPG) =7.8 mmol / L(Test on -1 Day). 5. have known allergies to compounds related to SY-008 capsules or multiple drug allergies, or have been treated with SGLT-1(sodium-glucose cotransporter-1) inhibitors in 1 year. 6. have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (such as hemorrhoids, inflammation of GI tract, tumor, history of surgery, habitual bellyache or diarrheal disorders, other motility disorders), endocrine, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs or of constituting a risk when taking the study medication or interfering with the interpretation of data. 7. have a history of alcohol abuse or drug abuse. 8. show evidence or test positive on any of the following: hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody (HCV), Treponema pallidum antibody (TP), HIV (HIV1 + 2) antibody. 9. have donated blood of 400 mL or more in the last 3 months or provided any blood donation within the last month from screening. 10. are subjects who have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females; 1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits) or are subjects unwilling to stop alcohol consumption 24 hours prior to dosing until the completion of each inpatient study period. 11. consume more than 10 cigarettes per day or the equivalent, or are unable or unwilling to refrain from nicotine during the study. 12. intend to use over-the-counter or prescription medications within 14 days prior to dosing or during the study. 13. subjects not agree to use reliable contraceptive methods (hormones or barriers or abstinence) during the study period and at least 1 month after administration. 14. women were positive for blood pregnancy test within 24 hours prior to enrollment. 15. pregnant or lactating women. 16. in the opinion of the investigator or sponsor, are unsuitable for inclusion in the study. |
Country | Name | City | State |
---|---|---|---|
China | The First Affiliated Hospital of Nanjing Medical University | Nanjing | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Suzhou Yabao Pharmaceutical R&D Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 | Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment. | 7 days | |
Secondary | area under curve (AUC) of SY-008 following oral administration of single ascending dose | to measure the study drug concentration in blood samples to be collected after drug administration. | 3 days | |
Secondary | Cmax of SY-008 following oral administration of single ascending dose | to measure the study drug concentration in blood samples to be collected after drug administration. | 3 days | |
Secondary | T1/2 of SY-008 following oral administration of single ascending dose | to measure the study drug concentration in blood samples to be collected after drug administration. | 3 days | |
Secondary | CL/F (Clearance rectified) of SY-008 following oral administration of single ascending dose | to measure the study drug concentration in blood samples to be collected after drug administration. | 3 days | |
Secondary | glucose levels following single dose of SY-008 | FPG AUC | 24 hours | |
Secondary | insulin secretion following single dose of SY-008 | insulin changes | 3 days | |
Secondary | C-peptide secretion following single dose of SY-008 | C-peptide change | 6 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05594446 -
Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
|
||
Completed |
NCT03975309 -
DHS MIND Metabolomics
|
||
Completed |
NCT01855399 -
Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes
|
N/A | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Recruiting |
NCT05007990 -
Caregiving Networks Across Disease Context and the Life Course
|
||
Active, not recruiting |
NCT04420936 -
Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program
|
N/A | |
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Completed |
NCT04903496 -
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
|
||
Completed |
NCT01437592 -
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT03390179 -
Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Recruiting |
NCT05294822 -
Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes
|
N/A | |
Completed |
NCT04427982 -
Dance and Diabetes/Prediabetes Self-Management
|
N/A | |
Completed |
NCT02356848 -
STEP UP to Avert Amputation in Diabetes
|
N/A | |
Completed |
NCT03292185 -
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
|
Phase 1 | |
Active, not recruiting |
NCT05477368 -
Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 |